Patricia Inacio, PhD,  science writer—

In a new study entitled “Polymorphonuclear Cell Functional Impairment in Relapsing Remitting Multiple Sclerosis Patients: Preliminary Data” researchers investigated how polymorphonuclear cells — important players of the innate immune system — are altered in multiple sclerosis patients. The study was published in the journal PLOS…

In a recent study entitled “Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy,” researchers unraveled a key role for the cytokine GM-CSF in multiple sclerosis progression, suggesting GM-CSF as a target of IFN-β therapy. The study was published in…

The Austrian Centre of Industrial Biotechnology (acib) developed a new purification method for pharmaceutical produced antibodies that promises to effectively decrease the high prices of these drugs in the market. Therapeutic antibodies revolutionized how doctors treat diseases affecting a large number of individuals, such as cancer and autoimmune…

A new study entitled “Mercury Exposure and Antinuclear Antibodies among Females of Reproductive Age in the United States” suggests mercury exposure by seafood may increase the risk of developing autoimmune diseases in women. The study was published in the journal Environmental Health Perspectives. Autoimmune disorders…

A new Multiple Sclerosis pilot study was awarded a $39,000 grant by the National Multiple Sclerosis Society to investigate how patients’ sensation in their feet while standing impacts balance and whether their ability to walk is improved through the use of vibrating insoles. Multiple Sclerosis is characterized by the destruction of the…

In a recent study entitled “Detection of protein aggregates in brain and cerebrospinal fluid derived from multiple sclerosis patients” a team of researchers reported to have detected soluble oligomers in both brain and cerebrospinal fluid samples from multiple sclerosis patients. The study was published in the…

A recent study entitled “STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation” describes a new subset of T helper immune cells – TH-GM – that express a particular cytokine profile with implications in therapeutics for multiple sclerosis. The study was…

In a poster session at the Annual meeting of the Society for Neuroscience in Washington, ENDECE Neural presented pre-clinical results showing their lead drug – NDC-1308 – induces remyelination in mouse models of demyelination disease, such as Multiple Sclerosis. Loss of myelin is the main characteristic of a group…

In a study entitled “Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination” the authors report to have found a new protein, Del-1, that reduces the severity of multiple sclerosis disease in a mouse model of the disease. The…

A team of researchers at the Tel Aviv University report the role of obesity as a major risk factor triggering and maintaining autoimmune diseases, such as Crohn’s Disease and multiple sclerosis. The study was published in Autoimmunity Reviews. In autoimmune diseases, the immune system reacts against the body…

A study entitled “Longitudinal Follow-up of a Cohort of Patients with Incidental Abnormal Magnetic Resonance Imaging Findings at Presentation and Their Risk of Developing Multiple Sclerosis” published in the International Journal of MS Care reports that asymptomatic patients accompanied by Magnetic Resonance Images suggestive of…

An encouraging experimental drug that is being developed for Multiple Sclerosis continues to show promise in being able to offer neuroprotective benefits — an effect that could slow and eventually cure MS. Masitinib, which is being developed by AB Science for numerous neurological indications, including Alzheimer’s disease, progressive multiple sclerosis, and amyotrophic…

A new human clinical trial testing the drug ATL1102 to treat Multiple Sclerosis was approved by FDA, carrying the promise of new therapeutics to affected patients. Antisense Therapeutics Limited (ANP) announced recently in a press release the FDA’s positive decision to approve their request to submit an Investigational…

Among autoimmune diseases, Multiple Sclerosis is one of the most progressive and debilitating, affecting between 300,000 and 400,000 people in the United States alone. The cause of the disease remains elusive to researchers, making it extremely difficult to research and develop effective therapies for treating symptoms and reversing neural…

A new study entitled, “Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases” published in the JAMA Neurology journal, reports that no association was observed between vaccinations and an increased risk for Multiple Sclerosis or other central nervous system…

The first and largest study on the association between Multiple Sclerosis (MS) and Uveitis was recently presented at the 18th annual meeting of the American Academy of Ophthalmology. The meeting was held at the McCormick Place in Chicago between October 17-21, 2014. Uveitis is a disorder characterized by inflammation of…

Much of the research and development focus for treating Multiple Sclerosis revolves around pharmaceuticals. However, the development and use of novel medical devices are also becoming a factor in treating the disease as well. A new study entitled “A dorsiflexion assist orthosis reduces the physiological cost…

A new study entitled “NAD+ protects against EAE by regulating CD4+ T-cell differentiation” published in October issue of Nature Communications reports that NAD+ can be a future therapeutic drug to treat Multiple Sclerosis. Multiple sclerosis (MS) is a type of autoimmune disease where the inner…

Researchers recently uncovered some curious new insights into environmental factors that may rise or lower the risk of developing Multiple Sclerosis. A new study entitled “Environmental exposures and the risk of multiple sclerosis investigated in a Norwegian case–control study” published in October issue of…

A new study entitled “Intestinal Barrier Dysfunction Develops at the Onset of Experimental Autoimmune Encephalomyelitis, and Can Be Induced by Adoptive Transfer of Auto-Reactive T Cells” published in September issue of PloS One, reports that disruption of intestinal homeostasis supports Experimental Autoimmune Encephalomyelitis, the prototypic…

Approximately 110 multiple genetic variations were previously identified by genome-wide association studies (GWAS) to be associated with Multiple Sclerosis (MS). Now, that number has increased, with more than 159 genetic variants identified, thanks to new research presented by Philip De Jager, M.D., of Brigham and Women’s Hospital, Harvard Medical…

Recent research reveals that placenta-based cell therapy is both safe and effective for treating both Relapsing-Remitting and progressive forms of MS. A new study entitled “Human Placenta-Derived Cells (PDA-001) for the Treatment of Adults With Multiple Sclerosis: A Randomized, Placebo-Controlled, Multiple-Dose Study” and published in August…

A new study, entitled “The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis” published online in JAMA Neurology, reports the effect of Glatiramer acetate therapy on B cells in relapsing-remitting multiple sclerosis (MS) patients. This first-of-its-kind study could…